中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Boston Children’s Hospital
合作者
Brigham and Women's Hospital

关键词

抽象

This is a study about the relationship of brain biomarkers with neuropsychological functioning in PKU. All participants will undergo MRI spectroscopy, will provide a blood specimen and will receive neuropsychological testing.

描述

Despite newborn screening and early initiation of treatment, many adolescents and adults with PKU experience some degree of neuropsychological dysfunction or mood disturbances. Blood phenylalanine (Phe) levels and low levels of tyrosine (Tyr) only partially explain why some individuals with PKU have these difficulties and others do not. In this study, the investigators will use a new approach involving magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) for measuring brain Phe (and other brain chemicals) in order to determine relationships between brain biomarkers and neuropsychological functioning and mood. Previously, brain Phe and Tyr could not be reliably measured by MRS methods, especially in concentrations likely to be found in individuals with treated PKU. This project will use an improved method for measuring brain Phe and Tyr. The investigators will use two-dimensional shift correlated magnetic resonance spectroscopy (COSY). COSY is a non-invasive method that allows for quantitative measurement of Phe, Tyr and other amino acids in the brain. This project has the potential to close one of the most important gaps in the knowledge of PKU, namely to define how PKU affects the brain. The aims of this study are to examine brain Phe and Tyr in individuals with PKU and in an age-matched healthy comparison group, and 2) determine the association of Phe and Tyr in distinct brain regions with measures of neuropsychological functioning and mood. Participants with PKU will receive 2 MRI scans with spectroscopy and the comparison group will receive 1 MRI scan with spectroscopy under fasting conditions. All participants will provide a blood specimen for blood amino acid determinations and will receive neuropsychological testing. The investigators will develop statistical models that can be applied in future studies to enhance understanding of PKU. This pilot study is important because it will provide evidence of the usefulness of COSY. COSY has the potential to explain individual differences in PKU, identify specific cognitive functions or mood disturbances related to high brain Phe or low brain Tyr, and offer an additional marker or endpoint for evaluating new treatments in clinical trials.

日期

最后验证: 09/30/2018
首次提交: 03/21/2017
提交的预估入学人数: 03/26/2017
首次发布: 03/30/2017
上次提交的更新: 10/17/2018
最近更新发布: 10/18/2018
实际学习开始日期: 10/24/2017
预计主要完成日期: 06/30/2018
预计完成日期: 06/30/2018

状况或疾病

Phenylketonuria

-

手臂组

干预/治疗
PKU Subjects
Subjects with PKU will be asked to undergo an MRI and blood draw on Day 1 and Day 2 of the study. They will also receive neuropsychological testing on Day 1 of the study
Controls
Controls will undergo only one MRI and blood draw on Day 1 of the study. They will also receive neuropsychological testing on Day 1 of the study.

资格标准

有资格学习的年龄 12 Years 至 12 Years
有资格学习的性别All
取样方式Non-Probability Sample
接受健康志愿者
标准

Inclusion Criteria:

1. Age 12-25 years

2. Not currently participating in a clinical trial

3. Capable of providing informed assent/consent

4. Able to undergo MRI procedures without sedation

5. Does not have metal implants (braces or permanent retainers made of MRI-compatible materials are permitted since we will not be doing procedures, such as DTI, affected by non-ferrous metals).

6. PKU Group: identified by newborn screening; received treatment within the first 30 days of life

7. PKU Group: Pre-treatment/off-diet blood Phe concentration at or above 600 umol/L

Exclusion Criteria:

1. Older than 25 years or younger than 12 years of age.

2. Currently participating in a clinical trial

3. Incapable of providing informed assent/consent

4. Pregnant women will be excluded

5. Not able to tolerate MRI procedures without sedation

6. Has metal implants or braces on teeth not compatible with MRI

7. Has any known contraindication for MRI

8. PKU Group: Pre-treatment/off-diet blood Phe concentration below 600 umol/L)

9. PKU Group: Not identified through newborn screening or treatment was initiated after 30 days of life

结果

主要结果指标

1. Neuropsychological functioning [1 day]

NIH Toolbox Cognitive Battery

2. Social/Emotional Outcome [1 day]

NIH PROMIS Questionnaires (Neuro QoL)

3. Blood Biomarkers [2 days]

Phenylalanine and Tyrosine (umol/L)

4. Brain Biomarkers [2 days]

Phenylalanine and Tyrosine (umol/L)

次要成果指标

1. Intellectual Functioning [1 day]

Full Scale IQ

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge